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INTRODUCTION
A new concept for the action of antipsychotics drugs that
do not induce motor side effects is dopamine system
stabilization (Stahl 2001; Stahl 2001). The brain normally
stabilizes dopamine neurotransmission by attaining a balance
between presynaptic and postsynaptic D2 receptor
stimulation. These 2 mechanisms act together: presynaptic
dopamine receptors are stimulated, and dopamine release
at specific post-synaptic sites is turned off, thus reducing
excessive dopamine activation in parts of the brain where
the concentration is too high yet permitting normal dopamine
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ABSTRACT:
Aripiprazole is a new anti psychotic with a unique receptor binding profile that combines partial agonistic activity at D2
receptor and 5-HT 1A receptor and potent antagonism at 5-HT 2A receptor. This receptor profile makes it possible for it
to act as a dopamine system stabilizer. Based on various short term and long term studies, aripiprazole   has been found to
be effective in schizophrenia and has no significant adverse effect on QTc prolongation, prolactin, serum lipids, and has a
low potential for weight gain. Present study aims to evaluate the efficacy and tolerability of aripiprazole (10-15mg/day) in
the treatment of Indian patients of schizophrenia and to see its effect on QTc interval, prolactin levels, serum lipids, plasma
sugar and weight gain in these patients. Outpatients with an ongoing/newly diagnosed ICD-10 Schizophrenia (n=136) were
randomly assigned to 10 or 15 mg dose of Aripiprazole for a period of six weeks. Clinical response was evaluated by the
Positive And Negative Symptoms Scale (PANSS), Clinical Global Impression (CGI) scale and safety was evaluated by
observing spontaneously reported adverse events and changes in various laboratory parameters. Switching schizophrenic
patients to aripiprazole (10/15 mg) from both conventional and atypical anti-psychotics was safe and well tolerated. Six
weeks after switching to aripiprazole, patients showed improvements in PANSS scores (P<0.001), EPS, prolactin levels
and weight over the baseline levels. No difference was seen in the 10 or 15mg dose groups. One hospitalization was
reported (due to hepatitis E). Common side effects reported were insomnia, somnolence, nausea, vomiting and diarrhea.
Aripiprazole is a safe and effective anti psychotic in Indian patients — both in newly diagnosed, as well as, in patients not
responding to or intolerant to other available typical and atypical antipsychotics.
Key words: Aripiprazole, Schizophrenia, Switch Study.
activity in other parts of the brain. The presynaptic, D2
receptors responsible for regulating dopamine release are
less sensitive in detecting dopamine than are postsynaptic
D2 receptors, so physiologic neurotransmission continues
until dopamine levels build up sufficiently to stimulate the
presynaptic D2 receptors, thereby turning off further
dopamine release.
In the brain, regional differences may occur in the activity
of dopamine neurons and the sensitivity of various
presynaptic and postsynaptic D2 receptors to dopamine,
especially during disease states and as a consequence of
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various drug treatments. The concept of dopamine system
stabilization is based on preserving or enhancing
dopaminergic neurotransmission where it is low (“too cold”)
and reducing dopaminergic neurotransmission where it is
too high (“too hot”). In terms of treating psychosis, the
goal is to reduce hyperactive dopamine neurons that mediate
psychosis and at the same time enhance underactive
dopamine neurons that mediate negative and cognitive
symptoms (mesocortical pathway) while preserving
physiologic function in dopamine neurons that regulate motor
movement and prolactin- all in the same brain at the same
time.
When dopamine is dysregulated in psychoses (e.g.,
schizophrenia), dopamine system stabilizers (DSSs), which
bind to D2 receptors in a manner that can be either
stimulating or antagonizing, are helpful. These stabilizers
are far different from receptor antagonists, which always
block the action  of dopamine completely and reduce output
from D2 receptors (“too cold”), and very different from
dopamine itself, which is a full agonist at D2 receptors that
creates maximum action (if the amount is high enough),
making the receptors “too hot”. DSSs, on the other hand,
theoretically create the desired dopamine balance. Thus,
when dopamine activity is too cold, a DSS increases
dopamine output, but to a level not as hot as real dopamine.
In the presence of maximum dopamine DSSs reduce the
amount until it is “just right”.
Pharmacologically, this mechanism is known as partial
agonist action, which means activation at low dopaminergic
tone and inhibition at high dopaminergic tone, thus stabilizing
dopamine output from either direction. Molecularly, the exact
mechanism of partial agonist binding to D2 receptors
remains somewhat obscure but is hypothesized to exploit
differences in D2 receptors presynaptically vs.
postsynaptically, in various brain regions, or in their affinities,
distribution, density, and tightness of coupling to a physiologic
output.
Clinically, the term partial agonist may be misinterpreted
because “partial” can imply weak or incomplete. DSSs,
however, are not less effective than other types of
antipsychotics. The prototypical member of this class
aripiprazole has been found to reduce psychosis as
effectively as other antipsychotics without causing motor
side effects in schizophrenia(Kane et al. 2002;  Ozdemir et
al. 2002). Moreover, aripiprazole has been shown to have
no adverse effect on prolactin levels, QTc prolongation,
serum lipids and sugar and has a low potential for weight
gain. All these beneficial characteristics has earned it a
label of “Third generation antipsychotic”.
The present study was to evaluate whether aripiprazole
behaves similarly in the Indian population as in the western
population and whether the recommended dose of 10-15mg/
day is safe and effective.
METHOD:
A total of 7 centres in India participated in this open,
randomized (to 10 or 15 mg aripiprazole), switch over
multicentric study.
Patients:
Eligible participants were male or female outpatients, 18 to
65 years of age, with diagnosis of  schizophrenia as defined
in ICD-10.
Categories of patients included:
1) Newly diagnosed
2) Patients who had achieved partial or no response to
treatment with typical and atypical anti psychotics
3) Subjects who did not tolerate the prescribed
antipsychotics.
Patients with history of more than one serious suicide
attempt, organic brain disease and any other psychiatric
disease, any chronic unstable medical illness and
unwillingness to provide informed consent were excluded
from the study. Patients taking epileptic medication and ECT,
pregnant women, patients with history of repeated non-
compliance with treatment and patients with clinically
significant laboratory abnormality were also excluded from
the study.
The study protocol was approved by the institutional review
boards for all participating study centers and by regulatory
authority of India. The patients gave a signed informed
consent before any study-related procedure including
screening could be undertaken.
Study Design
The study was a multicentric trial, spread over diverse
geographical locations in India. Patients underwent a
comprehensive psychiatric and physical examination and
appropriate hematology, biochemistry, urine pregnancy test
(females) and ECG examination. Patients meeting eligibility
criteria at screening were enrolled in the study. Category I
patients were started on drug therapy immediately  at a
dose of 10 or 15 mg and continued at the same dosage for
six weeks. Category II  & III patients were switched to
aripiprazole (10 or 15 mg/day) over a period of one
week(switch strategy outlined below). The drug was
continued on the randomized dose for a further 5 weeks.
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DROP OUTS  & WITHDRAWALS
Reasons Total Aripiprazole Aripiprazole
10 mg 15 mg
AE’s 2 1 1
Increased
psychotic
symptoms 2 0 2
Discontinuation
on Pts. Request 3 1 2
Poor compliance 1 0 1
Lost to follow-up 2 1 1
Total 10 3 7
Note: patient mentioned more than one reasons
Switch Strategy
Switch (for 7 days):
Aripiprazole (10 or 15 mg once daily) + previous drug
tapered over one week (at same dose for day 1 to 3; reduced
to half the dose for day 4 to 7, followed by discontinuation) 
After switch (for 35 days):
Once daily dose 10 or 15 mg of Aripiprazole
Follow-up visits
Follow-up visits were conducted after 1,2, 3, 4, 5 & 6 weeks
of treatment, during which efficacy and safety evaluations
were conducted. Efficacy assessments at each visit included
the PANSS scale, CGI-I and CGI-S scale. Adverse events
were enquired and recorded at every visit.
Primary Efficacy Measures
1) PANSS Scale
2) CGI –S score and CGI –I score.
3) Response rate: > 30% decrease in PANSS score
Safety and Tolerability Measures
All adverse events volunteered, observed and enquired
during the study or within 6 days of the last day of treatment
were recorded together with their date of onset, duration,
concurrent therapy, the investigator’s assessment of
severity, and the possible causative relationship to study
drug, and whether a change in dose or withdrawal of
treatment was required. A 12 lead ECG was done at baseline
and at the end of the study. Clinical laboratory tests, including
routine hematology, serum chemistry and liver function tests
were carried out at baseline and at end of study.
Statistical Analysis:
Intention to Treat (ITT) statistical analysis has been
performed on the data. Last Observation Carried Forward
(LOCF) principle has been used for those patients who
have taken the study drug for at least two weeks.
Demographic data is presented in the form of Mean ± S.D.
Significance between treatment groups for continuous type
data has been subjected to Student’s t-test & for Nominal
type data has been subjected to Chi-Square test or Fisher
Exact test. Since the data for PANSS is measured on ordinal
scale the data for this parameter has been subjected to
Non-Parametric test. The sum of ranks for all questions in
PANSS score at respective visits was subjected to Wilcoxon
sign rank test for finding the significance within the groups.
Subjecting the data to ANCOVA with baseline value as its
covariate tested significant difference between the
treatment groups. Change in severity of illness (CGI-S)
and global improvement (CGI-I) for both treatment groups
from baseline to last visit was subjected to chi-square test
for finding significance. Laboratory investigations data was
first checked for its normality. If found normal, then the
data was subjected to parametric test (paired T-test).
Otherwise, the data was subjected to Non-Parametric
(Wilcoxon Sing Rank) test for checking significance from
baseline to last visit.
Significance between the treatment groups for interval type
data has been subjected to student’s t test. Nominal type
data has been subjected to chi-square test. Fisher’s exact
test was used for categorical data where cell numbers were
small. All the statistical tests used at 5% significance level.
RESULTS
Demography
A total of 136 patients were randomized (balance
randomization) to receive either  10 or 15 mg/day  of
Aripiprazole in the study. Out of these,10 patients dropped
out from the study before 2 weeks of the Aripiprazole
Treatment. The dropouts have not been included in the
analysis. Reasons for the drop outs are mentioned in the
Table-3.
Twenty patients were lost to follow-up after completing
more than 2-weeks of aripiprazole treatment and have been
included in the analysis using the statistical technique of
last observation carried forward (LOCF). Out of the 126
patients who have been analysed, 65 patients were taking
10 mg aripiprazole once daily and 61 were taking 15 mg
aripiprazole once daily.67
The demographic data of patients who were analysed  is
presented in Table -1.
The average age of  the patients was 34±10 years. There
were more number of males than females in the study. The
median duration of illness was around 4 years. Three
categories of patients were enrolled as per the inclusion
criteria. There were 29 newly diagnosed patients, 16 patients
were intolerant to previous therapy and 81 patients were
partial-responder or non-responders to previous therapy.
The patients were equally distributed in the 10 mg & 15 mg
dose groups as regards age, sex, duration of illness and
category of patients.
Therapies from which the patients were switched to
aripiprazole included both typical and atypical antipsychotic
drugs
Table: 2.
Table 1.
DEMOGRAPHIC PROFILE OF PATIENTS
Total 10 mg 15 mg
(n=126) (n=65) (n=61)
Age (years) 34 ± 10 35±11 33±9
Males (n) 80 43 37
Females (n) 46 22 24
Duration of illness
(median months) 49 months 42 months 36 months
History of <1 suicide 5 4 1
attempt (n)
Category of Patients
Newly diagnosed (n) 29 18 11
Intolerant to previous 16 6 10
therapy (n)
Partial or non- 81 41 40
responders (n)
Many patients were on  more than one antipsychotic drug.
Most commonly administered previous therapies included
olanzapine , risperidone, haloperidol and trifluperazine.
Efficacy Evaluation:
Change in total PANSS score (from baseline) was
measured as the Efficacy end point for the Patients.
Aripiprazole treatment, in the dose of 10 and 15 mg for a
period of 6-weeks, consistently decreased total PANSS
score over the study duration. The decrease in PANSS
score (compared to baseline) reached statistical significance
(P<0.001) from week-2 (Figure-1).
Aripiprazole produced a similar effect on the Positive and
Negative sub-scale scores of PANSS.  Both the sub-scale
scores showing significant reduction over baseline, starting
from week-2(Figure-2).
On comparison of two dose groups as regards the reduction
in the PANSS scores it was seen that there was no
significant difference in the two treatment groups (10mg
and 15 mg)( Figure-3).
Therapies from which the patients were switched to aripiprazole
Drug Name No. of Patients
Chlorpromazine 7
Clozapine 20
Flupenthixol 6
Haloperidol 28
Olanzapine 50
Quetiapine 5
Risperidone 68
Trifluperazine 38
Ziprasidone 14
Note: Many patients were on more than one anti-psychotic drug.
Figure 1.
Change in Total PANSS - Score Over 6-Weeks of
Aripiprazole (10 mg /15 mg) Treatment
Figure 2.
Change in Sub-Scales Scores of PANSS  by Aripiprazole
(10 mg/ 15 mg) Treatment Over 6-Weeks
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CGI-S scores improved over 6-week treatment with
aripiprazole showing thereby a decrease in the disease
severity (Figure-4).
Both the dose groups  (10 mg and 15 mg)  showed equal
improvement  in the CGI-S scores (Figure-5).
CGI-I scores improved steadily over 6-week treatment with
aripiprazole, a reflection of the global improvement in the
symptomatology of the patients (Figure-6).
Both the dose groups  (10 mg and 15 mg) showed equal
improvement in the CGI-I scores (Figure-7).
Figure 4:
Change In CGI-S Scores Over 6-Weeks Of Treatment
With Aripiprazole(10 mg &15 mg)
Figure 5:
Comparison  of change in CGI-S scores by Aripiprazole in the
10 mg dose group with 15 mg dose group
Response rate (decrease in PANSS scores by >30%) to
aripiprazole after 6-weeks of therapy was more than 70%
in both the dose groups (10 mg and 15 mg) (Figure-8).
Switching schizophrenic patient to aripiprazole (10 mg and
15 mg) from both conventional (haloperidol, trifluperazine)
and atypical anti-psychotics (risperidone, olanzapine,
quetiapine) produced improvement in the symptomatology
over previous therapies. This is evident by the improvement
in PANSS score and CGI-I score over baseline (Figure-
9& 10).
Safety Evaluation:
No unexpected adverse event was reported. About 70%
of patients reported at least one adverse event during the
Figure 6.
Change In Mean CGI-I Scores Over 6-Weeks Of Treatment
With Aripiprazole(10 mg &15 mg)
Figure 7.
Comparison  of change in CGI-I scores by Aripiprazole in the
10 mg dose group with 15 mg dose group
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6-weeks of treatment with aripiprazole (Table-4).  15-mg
dose group showed a slightly higher proportion of adverse
events (72%) as compared to 10-mg dose group (66%).
The most commonly reported adverse events were fatigue
Figure 9:
Change in PANSS score on Switching to Aripiprazole
Figure 10:
Change in CGI-I Score on Switching to Aripiprazole
Table 4.
ADVERSE EVENTS (AES)
Major AE’s observed Total 10 mg 15 mg
(n=126) AripiprazoleAripiprazole
(n=65) (n=61)
Patient having AE’s  n (%) 87(69%) 43(66%) 44(72%)
Dropout due to AE’s n (%) 2 (2%) 1(1%) 1(1%)
Fatigue 27(32%) 13(20%) 14 (23%)
Insomnia 24(27%) 13(20%) 21 (34%)
Headache 21(24%) 16(24%) 13(21%)
Nausea / Vomiting 17(19%) 14(22%) 8(13%)
Tremor 18(20%) 7(11%) 9(14%)
Rigidity 4(5%) 3(5%) 1(1%)
Akathisia 4(5%) 2(3%) 2(3%)
Dyskinesia 0(0%) 0(0%) 1(1%)
Decrease in libido 1(1%) 0(0%) 1(1%)
Constipation 10(12%) 7(11%) 3(5%)
Blurred vision 1(1%) 0(0%) 1(1%)
Hepatitis 1(1%) 1(1%) 0(0%)
Other AE’s 33(37%) 16(25%) 17(28%)
(32%), insomnia (27%), headache (24%), nausea/vomiting
(19%), tremor (20%), rigidity (5%), akathisia (5%),
constipation (12%). There was no significant difference in
the two dose groups.
No clinically relevant change was observed after 6-weeks
Table 5 : Laboratory Investigations at baseline and after 6 weeks of treatment
Lab Parameters At Screening
At Week-6 (n=106)
Significance
(n=126) e
Mean S.D. Mean S.D. (P Value)
QTc Interval 400.46 43.39 396.78 49.69 0.456
Hb (gm%) 12.89 1.53 12.73 1.49 0.453
RBC-Total count (cell/mm3) 4.67 0.66 4.69 0.59 0.866
WBC-Total Amount (cell/mm3) 7214.18 1446.38 7463.83 1487.05 0.211
WBC-DC (N/P) 64.73 7.11 65.81 7.45 0.862
WBC-DC (L) 29.72 6.70 28.43 6.49 0.534
WBC-DC (M) 3.48 2.34 4.10 2.24 0.883
WBC-DC (E) 2.84 2.55 2.84 2.72 0.350
WBC-DC (B) 3.94 2.14 2.00 0.00 —
SGOT (U) 29.34 10.67 26.13 9.90 0.016
SGPT (U) 29.89 13.58 29.28 14.11 0.970
Serum alkaline phosphatase (U) 117.06 78.23 107.56 74.10 0.928
Total bilirubin (mg%) 0.58 0.21 0.52 0.20 0.022
Serum Creatinine (mg%) 0.78 0.26 0.70 0.30 0.023
Blood Urea (mg%) 21.99 6.21 21.07 6.33 0.388
Blood Sugar (Fasting) 93.86 30.21 86.70 23.45 0.106
Prolactin 18.94 17.09 9.65 6.66 0.000
Serum Cholesterol 187.84 40.64 179.43 38.04 0.094
Serum Triglycerides 139.99 77.54 136.87 75.44 0.603
Serum HDL Cholestrol 44.29 10.52 49.88 32.30 0.268
Serum LDL Cholestrol 99.92 39.09 100.62 32.84 0.696
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Patients showing side effects at the baseline with the
previous therapies showed improvement with the
aripiprazole treatment(10 mg and 15 mg)(Table-6).
DISCUSSION:
Classical neuroleptics, known as conventional
antipsychotics, bind to D2 receptors throughout the brain
as powerful, long-acting antagonists. Unfortunately, the
blocking is often nonspecific, which is typical of conventional
antipsychotic actions. Thus, when D2 receptors in
nigrostriatal pathway are also blocked, a penalty is paid in
motor side effects, namely extrapyramidal reactions,
pseudoparkinsonism, and ultimately, tardive dyskinesia.
Ever since the motor complications of conventional
antipsychotics were recognized attempts have been made
to preserve their motor side effects. Second generation
antipsychotics, known as atypical antipsychotics, bind better
to D2 receptors in parts of the brain that control psychosis
than in parts of the brain that causes motor side effects.
Figure 13:   Change in Weight on Switching to Aripiprazole
of aripiprazole treatment in the laboratory parameters like
QTc interval, hematology, Serum biochemistry and plasma
lipid profile(Table-5). However, there was a significant
reduction (from baseline) in prolactin levels after aripiprazole
therapy(P<0.0001).
There was a non-significant decrease in the mean body
weight after 6-weeks of aripiprazole therapy (10 mg and
15 mg)(Figure-11).
Figure 11:
Change in Weight after 6-weeks of treatment with
Aripiprazole (10 mg & 15 mg)
Around 50% of patients had no change in the body weight,
40% had a weight loss over baseline, 10% had a weight
gain and 2% had significant weight gain(more than 7%
increase in body weight) (Figure-12 &13).
Most of the adverse events reported with aripiprazole (10
mg and 15 mg) were mild to moderate in severity, were not
serious, did not require discontinuation of therapy,  required
no treatment, were transient in nature and were unlikely to
be related to the study drug(Figure-14 & 15).
Side Effects Baseline Week-6
Amennorhea 2 1
Drowsiness 2 0
Dry mouth 1 0
Tremor 7 2
Rigidity 3 0
Body Ache 1 0
Sedation 1 0
Total 17 3
Figure 12:
Changes in the  Body Weight in Patients After 6-weeks of
Aripiprazole Therapy
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Such differential binding is a consequence of reduction of
D2 receptor antagonism where it is not desired, either by
simultaneous blockade of 5-HT2A receptors, or by short-
acting blockade at D2 receptor, called “hit-and-run”
antagonism. For these reasons, atypical antipsychotics have
become the current standard of treatment of schizophrenia.
However, there are still some aspects of the atypical
antipsychotics which call for improvement, including — QT
prolongation by ziprasidone; increase in serum prolactin by
risperidone; deranged lipid profile by olanzapine and
quetiapine; weight gain by olanzapine, quetiapine and
risperidone; nonselective receptor binding (High muscarinic
receptor affinity   of olanzapine, high alfa-adrenergic
receptor affinity of risperidone, olanzapine, quetiapine and
ziprasidone),
Third-generation antipsychotics are dopamine system
stabilizers (DSSs). They block D2 receptors sufficiently
where dopamine activity needs to be reduced (mesolimbic
pathway), and thereby produce an antipsychotic action.
However, DSSs do not simultaneously reduce dopamine
activity in those brain regions where normal dopamine levels
those brain where normal dopamine levels are needed
(nigrostriatal pathway) and thus do not cause motor side
effects. DSSs may even provide a modest boost in dopamine
activity in areas of the brain where it needs to be increased
(mesocortical pathway), and thus improve the negative and
cognitive symptoms of schizophrenia.
Aripiprazole is a potentially novel antipsychotic with a
mechanism of action that differs from the currently
marketed typical and atypical antipsychotics. Biochemically,
aripiprazole has been shown to be a partial agonist at
members of the D2 family of dopamine receptors (Lawler
et al. 1999; Burris et al 2002). In addition, Aripiprazole has
been shown to exhibit partial agonists activity on the
spontaneous release of prolactin from isolated rat anterior
pituitary slices (Burris et al 2002). In vivo, Aripiprazole has
been shown to exhibit antagonistic properties in animal
models of dopaminergic hyperactivity (Ozdemir et al. 2002).
Previously reported phase – II and III clinical data
demonstrated Aripiprazole to be superior to placebo for
improving PANSS total score (Ozdemir et al. 2002). All
known effective antipsychotic act at D2 receptors. A novel
concept for an antipsychotic without motor side effects is
to stabilize these receptors rather than block them harshly.
The present switch-over study showed that switching
schizophrenic patient to aripiprazole from both conventional
and atypical anti-psychotics is safe and well tolerated.
Switching to aripiprazole over one week with tapering dose
of previous drug was safe and well tolerated.
Aripiprazole offers advantages over presently available
typical and atypical antipsychotic drugs. Six weeks after
switching to aripiprazole, patients showed improvements in
PANSS scores, CGI-I scores, Extra Pyramidal Symptoms,
prolactin levels and weight over previous therapies.
Aripiprazole was effective against both positive and
negative symptoms of schizophrenia.
The two dose groups 10 mg and 15 mg showed equal
efficacy and safety.
Safety summary:
No serious or unexpected adverse event was reported
during the study. Most common side effects were insomnia,
fatigue, tremor and headache.
Most of the adverse events reported with aripiprazole (10
mg and 15 mg) were mild to moderate in severity, were not
serious, did not require discontinuation of therapy,  required
no treatment, were transient in nature and were unlikely to
be related to the study drug.
No significant adverse effect was observed on QTc
prolongation, prolactin, serum lipids, renal function and
hepatic function.
Aripiprazole has low potential for Extra Pyramidal
Symptoms as evidenced by a very low rate of EPS in the
study. It also has a low potential for weight gain.
The findings of the study are similar to the findings reported
in the literature both in terms of efficacy and safety
(McGavin et al. 2002; Drugs 2002).  Switch over studies
are becoming an important tool for evaluating new drugs
because of  their closeness to the clinical situations. They
are also more acceptable to the patients because of the
lack of  a placebo arm.
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